Replies to post #52937 on Biotech Values

[DewDiligence]

>Other C1-INHs are in development for HAE, but we believe LEVP will likely receive 7 years of Orphan exclusivity in the U.S. for Cinryze.<

Pharming obviously disagrees. One possibility is that the FDA grants separate orphan exclusivity for prophylactic HAE and acute HAE, although this seems unjustified by the orphan regs themselves.

Comments?